---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053197"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:04:29.062394+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Axsome Q1 net product revenue $75M (+160% YoY); net loss $68.4M; pipeline milestones on track

## Summary
- Auvelity net sales $53.4M (+240% YoY); Sunosi net revenue $21.6M (+64% YoY).
- Net loss $68.4M ($1.44/diluted share) vs $11.2M loss in Q1 2023 which included $62M one-time gain.
- Cash $331.4M at March 31, 2024; company expects funds to support operations into cash flow positivity.
- NDA resubmission for AXS-07 in migraine and NDA submission for AXS-14 in fibromyalgia targeted for Q2 2024.
- Positive Phase 3 SYMPHONY trial of AXS-12 in narcolepsy; Phase 3 ACCORD-2 for AXS-05 in Alzheimer's agitation initiated.

## SEC filing metadata
- accession: 0000950170-24-053197
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024053197/0000950170-24-053197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024053197/axsm-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053197
- JSON: https://secwatch.observer/filing/0000950170-24-053197.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053197.txt

## Key facts
- Earnings Releases
  Axsome Therapeutics, Inc. reported first quarter of 2024 results: revenue $75.0 million, net income $68.4 million, EPS $(1.44) per share.
  - Period: first quarter of 2024
  - Revenue: $75.0 million
  - Net income: $68.4 million
  - EPS: $(1.44) per share
  - Result: reported results
  source text: Total net product revenue for the first quarter of 2024 was $75.0 million, representing 160% year-over-year growth.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017024053197/0000950170-24-053197-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.